Eli Lilly (LLY.US) cuts Zepbound entry dose price, intensifying competition in the weight-loss drug industry and increasing industry pressure.

According to the Wisdom Financial App, as competition with rival Novo Nordisk (NVO.US) intensifies, Eli Lilly (LLY.US) has once again lowered the introductory price of its weight loss drug Zepbound.